Fresenius Medical Care AG & Co. KGAA (FMS)
Fresenius Medical Care AG & Co. KGAA R&D Expense: 28.52M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
FMS R&D Expense Rankings
| Overall | 16th percentile | 1467 of 1763 |
| Sector | 16th percentile | 345 of 413 in Healthcare |
| Industry | 0th percentile | 4 of 4 in Specialized Health Services |
FMS R&D Expense Range, Past 5 Years
| Minimum | 14.56M | Jun 2007 |
| Maximum | 30.30M | Dec 2011 |
| Average | 23.16M |
About R&D Expense
R&D expenses are a line item from many companies' income statements.
R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.
Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.
An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More
You may also be interested in these FMS related companies
FMS News
Auriga Maintains a 'Buy' on Affymax, Inc. (AFFY); Milestone Payments Drive Q1 Upside; Continue Seeing Market Opp for Omontys
May 08, 10:42AM Street Insider
May 08, 10:42AM Street Insider
Fresenius Medical Care and Celebrity Chef Aaron McCargo Jr. Offer Tips for Budget-Friendly Cooking on a Renal Diet
Mar 15, 12:58PM Business Wire
Mar 15, 12:58PM Business Wire
Think $FMS will challendge 200-EMA in not distant future. Look at yesterday's volume
about 76 days ago by britepathos
about 76 days ago by britepathos
$WPRT No Nat gas act, no subsidies, no profit, not this year. Graphite stocks for electric car batteries are the hot ticket now $NGC, $FMS
about 77 days ago by kel4003
about 77 days ago by kel4003
Fresenius Medical Care Offers Five Tips to Help Slow the Progression of Kidney Disease
Feb 29, 10:30AM Business Wire
Feb 29, 10:30AM Business Wire
Dividends of Death: Yields of 3.19% to 5.59% on Your Neighbor’s Unhealthy Lifestyle http://stks.co/2OgN $PEP $MO $HI $FMS $DVA $CAG $ABV
about 105 days ago by ycharts
about 105 days ago by ycharts
Aetna and Fresenius Medical Care Begin Chronic Kidney Disease Management Program
Feb 10, 11:03AM Business Wire
Feb 10, 11:03AM Business Wire
Fresenius Medical Care Salutes Patients Who Prioritize Fitness and Health
Jan 19, 9:00AM Business Wire
Jan 19, 9:00AM Business Wire
Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program
Jan 09, 3:00PM PR Newswire
Jan 09, 3:00PM PR Newswire
Fresenius Medical Care's Centenarian Patients Are a Testament to Success of Dialysis Treatments
Dec 23, 2:45PM Business Wire
Dec 23, 2:45PM Business Wire
U.S. Medical Testing Laboratory Earns Second Global Accreditation for Quality and Competency
Dec 06, 9:00AM Business Wire
Dec 06, 9:00AM Business Wire
Fresenius Medical Care Launches Healthy Lifestyle Initiative and Partnership with Celebrity Chef Aaron McCargo Jr.
Nov 30, 9:33AM Business Wire
Nov 30, 9:33AM Business Wire
Fresenius Medical names Franklin W. Maddux, M.D., as Chief Medical Officer
Nov 16, 11:32AM FlyOnTheWall
Nov 16, 11:32AM FlyOnTheWall
$FMS http://chart.ly/cu5f2do Retested prior breakout from cup pattern, setting up for new highs, strong sector
about 421 days ago by ToddinFL
about 421 days ago by ToddinFL
$FMS http://chart.ly/2mhfmbe Fresenius Medical Probing New Highs - Breaking Out
about 642 days ago by OptionRadar
about 642 days ago by OptionRadar
$FMS - Fresenius Medical Cup and Handle Watch into ESRD Bundled Pricing Release - http://chart.ly/2c973h
about 691 days ago by OptionRadar
about 691 days ago by OptionRadar
wow, i pitched them 2 days ago.....RT @djacome dialysis plays case u forgot $DVA $DCAI $FMS
about 776 days ago by djacome
about 776 days ago by djacome
In NEJM, FDA concerned w/kidney patient anti-anemia (epo) drug use, will convene advisory committee. $AMGN $DVA $FMS
about 873 days ago by HEALTH_NOTES
about 873 days ago by HEALTH_NOTES
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| FMS | 68.06 | +1.19 | +1.78% | 20.07B |
| EXLP | 20.60 | -0.03 | -0.15% | 861.92M |
| EXL | 11.54 | -0.04 | -0.35% | 388.16M |
| EXK | 9.08 | +0.13 | +1.45% | 785.00M |
| EXH | 12.16 | +0.54 | +4.65% | 746.82M |
| EXFO | 6.18 | +0.09 | +1.48% | 175.70M |
| EXEL | 4.49 | -0.12 | -2.60% | 684.22M |
| EXE | 3.58 | +0.04 | +1.27% | 37.70M |
| EXC | 36.76 | -0.14 | -0.38% | 31.42B |
| EXBD | 38.03 | +0.14 | +0.37% | 1.262B |
